8 research outputs found

    Perceptions of Latina K-12 Leaders' Experiences with Mentorship and Career Advancement

    Get PDF
    The purpose of the study reported in this article was to explore Latina leaders' perspectives about their mentorship and career advancement in K-12 education. Potential school administrators who are Latina are at particular risk to achieve a position of leadership within the educational setting for a variety of reasons (Méndez-Morse, 2000; 2004; Magdaleno, 2011). This article describes how six Latina leaders within California describe their mentoring and career progression, including their perceived barriers and sources of support from family and other mentors. Implications are presented for purposes of building the capacity of Latina K-12 school leadership in a way that is reflective of the ethnic community they serve

    Burn-activated neutrophils and tumor necrosis factor-α alter endothelial cell actin cytoskeleton and enhance monolayer permeability

    No full text
    Background: This study examined the hypothesis that exposure of an endothelial cell (EC) monolayer to tumor necrosis factor-α (TNF-α) and that burn-activated neutrophils alter EC actin cytoskeleton and enhance the permeability of the monolayer. Methods: Neutrophils were harvested from rats that had undergone a 45% surface area burn (BURN-neutrophil) or uninjured control rats. ECs were grown on polyester filters or fibronectin-coated glass slides and exposed for 4 hours to media, TNF-α (100 ng/mL), or TNF-α plus BURN-neutrophil or uninjured control rats (107 cells). Monolayer permeability was assessed by measuring the flux of albumin across the cells. EC surface area and microfilament number and length were determined by the staining of actin microfilaments with rhodamine phalloidin followed by fluorescent microscopy. Results: The amount of albumin that moved across the monolayer in response to TNF-α plus BURN-neutrophil was twice that of media alone (P <.05) or TNF-α alone (P <.05). The number and length of actin microfilaments in ECs exposed to TNF-α plus BURN-neutrophil were significantly less than that of cells exposed to media alone or TNF-α alone. Conclusions: These data are consistent with a hypothesis that TNF-α plus BURN-neutrophil affect endothelial monolayer permeability by altering EC actin cytoskeletal organization. (Surgery 2000;128:259-65.

    Glucagon-Like Peptide 1 Interacts with Ghrelin and Leptin to Regulate Glucose Metabolism and Food Intake through Vagal Afferent Neuron Signaling

    No full text
    Emerging evidence has suggested a possible physiologic role for peripheral glucagon-like peptide 1 (GLP-1) in regulating glucose metabolism and food intake. The likely site of action of GLP-1 is on vagal afferent neurons (VANs). The vagal afferent pathway is the major neural pathway by which information about ingested nutrients reaches the central nervous system and influences feeding behavior. Peripheral GLP-1 acts on VANs to inhibit food intake. The mechanism of the GLP-1 receptor (GLP-1R) is unlike other gut-derived receptors; GLP-1Rs change their cellular localization according to feeding status rather than their protein concentrations. It is possible that several gut peptides are involved in mediating GLP-1R translocation. The mechanism of peripheral GLP-1R translocation still needs to be elucidated. We review data supporting the role of peripheral GLP-1 acting on VANs in influencing glucose homeostasis and feeding behavior. We highlight evidence demonstrating that GLP-1 interacts with ghrelin and leptin to induce satiation. Our aim was to understand the mechanism of peripheral GLP-1 in the development of noninvasive antiobesity treatments

    Empagliflozin in Patients with Chronic Kidney Disease

    No full text
    Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to &lt; 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of &amp; GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P &lt; 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo
    corecore